和黄医药（中国）近日宣布签署一项重大合作协议。根据协议条款，该公司将获得1.1亿美元的 upfront 预付款，这笔资金将立即到账。除此之外，协议的潜在总价值相当可观——若所有里程碑节点均顺利达成，后续里程碑付款总额最高可达13亿美元。更为值得关注的是，协议中还包含了基于未来销售业绩的特许权使用费安排，这为和黄医药提供了持续性的收入来源。整个交易结构设计精巧，既保证了短期的现金流支撑，又为长期发展预留了广阔的业绩增长空间。
和黄医药（中国）近日宣布签署一项重大合作协议。根据协议条款，该公司将获得1.1亿美元的 upfront 预付款，这笔资金将立即到账。除此之外，协议的潜在总价值相当可观——若所有里程碑节点均顺利达成，后续里程碑付款总额最高可达13亿美元。更为值得关注的是，协议中还包含了基于未来销售业绩的特许权使用费安排，这为和黄医药提供了持续性的收入来源。整个交易结构设计精巧，既保证了短期的现金流支撑，又为长期发展预留了广阔的业绩增长空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.